Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124913762 | 12491376 | 2 | F | 20160902 | 20160623 | 20160915 | EXP | IL-JNJFOC-20160614388 | JANSSEN | FILANOVSKY K, MILLER EB, SIGLER E, BERREBI A, SHVIDEL L. INCIDENCE OF PROFOUND HYPOGAMMAGLOBULINEMIA AND INFECTION RATE IN LYMPHOMA PATIENTS FOLLOWING THE COMBINATION OF CHEMOTHERAPY AND RITUXIMAB. RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY APR-2016;11 (2):228-235. | 58.00 | YR | A | M | Y | 0.00000 | 20160915 | MD | IL | IL |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124913762 | 12491376 | 1 | PS | DOXORUBICIN HYDROCHLORIDE. | DOXORUBICIN HYDROCHLORIDE | 1 | Unknown | N | 50718 | LIPOSOME INJECTION | |||||||||
| 124913762 | 12491376 | 2 | SS | RITUXIMAB | RITUXIMAB | 1 | Unknown | 0 | UNSPECIFIED | ||||||||||
| 124913762 | 12491376 | 3 | SS | RITUXIMAB | RITUXIMAB | 1 | Unknown | FOR A PERIOD OF 15 MONTHS- MAINTENANCE THERAPY | 0 | UNSPECIFIED | |||||||||
| 124913762 | 12491376 | 4 | SS | CYCLOPHOSPHAMIDE. | CYCLOPHOSPHAMIDE | 1 | Unknown | 0 | UNSPECIFIED | ||||||||||
| 124913762 | 12491376 | 5 | SS | PREDNISONE. | PREDNISONE | 1 | Unknown | 0 | UNSPECIFIED | ||||||||||
| 124913762 | 12491376 | 6 | SS | ONCOVIN | VINCRISTINE SULFATE | 1 | Unknown | 0 | UNSPECIFIED |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124913762 | 12491376 | 1 | Diffuse large B-cell lymphoma stage IV |
| 124913762 | 12491376 | 2 | Diffuse large B-cell lymphoma stage IV |
| 124913762 | 12491376 | 3 | Diffuse large B-cell lymphoma stage IV |
| 124913762 | 12491376 | 4 | Diffuse large B-cell lymphoma stage IV |
| 124913762 | 12491376 | 5 | Diffuse large B-cell lymphoma stage IV |
| 124913762 | 12491376 | 6 | Diffuse large B-cell lymphoma stage IV |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124913762 | 12491376 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124913762 | 12491376 | Hypogammaglobulinaemia | |
| 124913762 | 12491376 | Off label use | |
| 124913762 | 12491376 | Pneumonia | |
| 124913762 | 12491376 | Product use issue | |
| 124913762 | 12491376 | Respiratory tract infection |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |